194 related articles for article (PubMed ID: 22025272)
1. Evaluating the effects of mixed osteolytic/osteoblastic metastasis on vertebral bone quality in a new rat model.
Wise-Milestone L; Akens MK; Rosol TJ; Hojjat SP; Grynpas MD; Whyne CM
J Orthop Res; 2012 May; 30(5):817-23. PubMed ID: 22025272
[TBL] [Abstract][Full Text] [Related]
2. Local treatment of mixed osteolytic/osteoblastic spinal metastases: is photodynamic therapy effective?
Wise-Milestone L; Akens MK; Lo VC; Yee AJ; Wilson BC; Whyne CM
Breast Cancer Res Treat; 2012 Jun; 133(3):899-908. PubMed ID: 22058005
[TBL] [Abstract][Full Text] [Related]
3. Multimodal μCT/μMR based semiautomated segmentation of rat vertebrae affected by mixed osteolytic/osteoblastic metastases.
Hojjat SP; Foltz W; Wise-Milestone L; Whyne CM
Med Phys; 2012 May; 39(5):2848-53. PubMed ID: 22559657
[TBL] [Abstract][Full Text] [Related]
4. New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft.
LeRoy BE; Thudi NK; Nadella MV; Toribio RE; Tannehill-Gregg SH; van Bokhoven A; Davis D; Corn S; Rosol TJ
Prostate; 2006 Aug; 66(11):1213-22. PubMed ID: 16683269
[TBL] [Abstract][Full Text] [Related]
5. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.
Whang PG; Schwarz EM; Gamradt SC; Dougall WC; Lieberman JR
J Orthop Res; 2005 Nov; 23(6):1475-83. PubMed ID: 16005175
[TBL] [Abstract][Full Text] [Related]
6. A single pretreatment by zoledronic acid converts metastases from osteolytic to osteoblastic in the rat.
Nyangoga H; Blouin S; Libouban H; Baslé MF; Chappard D
Microsc Res Tech; 2010 Aug; 73(8):733-40. PubMed ID: 19953666
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
8. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone.
Gamradt SC; Feeley BT; Liu NQ; Roostaeian J; Lin YQ; Zhu LX; Sharma S; Dubinett SM; Lieberman JR
Anticancer Res; 2005; 25(1A):107-15. PubMed ID: 15816526
[TBL] [Abstract][Full Text] [Related]
9. Role of Wnts in prostate cancer bone metastases.
Hall CL; Kang S; MacDougald OA; Keller ET
J Cell Biochem; 2006 Mar; 97(4):661-72. PubMed ID: 16447163
[TBL] [Abstract][Full Text] [Related]
10. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
Kitazawa S; Kitazawa R
J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
Keller ET; Brown J
J Cell Biochem; 2004 Mar; 91(4):718-29. PubMed ID: 14991763
[TBL] [Abstract][Full Text] [Related]
13. Osteolytic and osteoblastic bone metastases: two extremes of the same spectrum?
Ortiz A; Lin SH
Recent Results Cancer Res; 2012; 192():225-33. PubMed ID: 22307378
[TBL] [Abstract][Full Text] [Related]
14. Tumor-bone cellular interactions in skeletal metastases.
Chirgwin JM; Mohammad KS; Guise TA
J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):308-18. PubMed ID: 15615499
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
Thudi NK; Martin CK; Nadella MV; Fernandez SA; Werbeck JL; Pinzone JJ; Rosol TJ
Prostate; 2008 Jul; 68(10):1116-25. PubMed ID: 18461562
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin in prostate cancer bone metastasis.
Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
[TBL] [Abstract][Full Text] [Related]
17. Micro-CT combined with bioluminescence imaging: a dynamic approach to detect early tumor-bone interaction in a tumor osteolysis murine model.
Fritz V; Louis-Plence P; Apparailly F; Noël D; Voide R; Pillon A; Nicolas JC; Müller R; Jorgensen C
Bone; 2007 Apr; 40(4):1032-40. PubMed ID: 17251073
[TBL] [Abstract][Full Text] [Related]
18. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
[TBL] [Abstract][Full Text] [Related]
19. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
[TBL] [Abstract][Full Text] [Related]
20. Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions.
Yonou H; Ochiai A; Goya M; Kanomata N; Hokama S; Morozumi M; Sugaya K; Hatano T; Ogawa Y
Prostate; 2004 Mar; 58(4):406-13. PubMed ID: 14968441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
